Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1904 in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma
NCT07520357Phase 2Not yet recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Apr 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of garetatug rezetecan in neuroendocrine carcinoma (NEC), sponsored by Beijing Gaobo Hospital. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
garetatug rezetecan
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT07520357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07520357.